(19)

(11)

EP 4 185 326 A1

(12)

(43) Date of publication: 31.05.2023 Bulletin 2023/22 (21) Application number: 21846587.0 (22) Date of filing: 23.07.2021

(51) International Patent Classification (IPC):  A61K 39/395(2006.01) C07K 14/725(2006.01) (52) Cooperative Patent Classification (CPC): C07K 14/705; C07K 2319/33; C07K 2319/03; C07K 2317/73; C07K 16/30; A61K 2039/5156; A61P 35/00; C07K 14/7051; C07K 2317/569; C07K 2317/622; A61K 39/001168; A61K 2039/5158; C12N 2510/00; C12N 5/0636; A61K 35/17; A61K 45/06   C-Sets: A61K 35/17, A61K 2300/00; (86) International application number: PCT/US2021/042973 (87) International publication number: WO 2022/020720 (27.01.2022 Gazette 2022/04)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: KH MA MD TN (30) Priority: 24.07.2020 US 202063056266 P 10.12.2020 US 202063123751 P (71) Applicant: TCR2 Therapeutics Inc. Cambridge, Massachusetts 02142 (US)	(72) Inventor: QUINTÁS-CARDAMA, Alfonso Cambridge, Massachusetts 02142 (US) (74) Representative: Leonard, Thomas Charles et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL London WC1X 8NL (GB)